160 results on '"Ghelli Luserna di Rorà, Andrea"'
Search Results
2. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
3. CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
4. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
5. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
6. ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment
7. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients
8. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
9. The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
10. ETV6::ABL1 -Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.
11. Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
12. Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
13. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
14. Additional file 1 of CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
15. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
16. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
17. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
18. Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
19. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
20. Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
21. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
22. Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma
23. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia
24. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future
25. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope
26. Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial
27. Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia
28. The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells
29. Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
30. Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.
31. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1and cohesin/DNA damage mutations
32. Role of DNA Damage Response in Cancer and Healthy Stem Cells: Genome Stability, Tumor Development and Drug Resistance
33. The Inhibition of Chk1/Chk2 and Wee-1 Kinases as a Promising Therapy for the Treatment of Adult Acute Lymphoblastic Leukemia
34. Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia.
35. Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.
36. Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.
37. Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.
38. Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL)
39. The Inhibition of Chk1/Chk2 and Wee-1 Kinases as a Promising Therapy for the Treatment of Adult Acute Lymphoblastic Leukemia
40. Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs
41. Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations
42. Abstract 4507: New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients
43. Abstract 368: Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy
44. Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML).
45. Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.
46. Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT).
47. A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult “Triple Negative” Acute Lymphoblastic Leukemia Subgroups
48. Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies
49. Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
50. DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.